Melanoma drug Vemurafenib may increase risk of squamous cell carcinoma

According to a study published in the New England Journal of Medicine, Vemurafenib (Zelboraf) speeds the growth of squamous cell carcinoma. HealthDay explained that “roughly one-quarter of patients who take the medication develop a troublesome side effect: secondary skin cancers called squamous cell carcinomas.”